Irloxacin

CAS

91524-15-1

Catalog Number

ACM91524151

Category

Others

Molecular Weight

300.29

Molecular Formula

C16H13FN2O3

MSDS COA Spec Sheet

If you have any other questions or need other size, please get a quote.

Specification

Description

Irloxacin is a new quinolone derivative, and shows greater activity with an acid pH. It has a good in vitro antimicrobial spectrum against both gram-positive and gram-negative bacteria. In vitro activity of irloxacin against mycobacteria (20 M. tuberculosis, 17 M. avium, 5 Mycobacterium bovis, 5 Mycobacterium chelonae, 5 Mycobacterium fortuitum and 1 Mycobacterium gadium) using the Bactec at pH 6.8 and 5.0, with other quinolones (ofloxacin, ciprofloxacin, pefloxacin and 27753 RP) were compared. All quinolones tested showed good activity against mycobacteria at pH 6.8 and 5.0. Irloxacin at pH 5.0 had a greater activity against M. avium.

Synonyms

E 3432; E3432; E-3432; Irloxacin; Pirfloxacin

IUPAC Name

3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1H-pyrrol-1-yl)-

Canonical SMILES

O=C(C1=CN(CC)C2=C(C=C(F)C(N3C=CC=C3)=C2)C1=O)O

InChI

InChI=1S/C16H13FN2O3/c1-2-18-9-11(16(21)22)15(20)10-7-12(17)14(8-13(10)18)19-5-3-4-6-19/h3-9H,2H2,1H3,(H,21,22)

InChI Key

RZLHGQLYNZQZQQ-UHFFFAOYSA-N

Solubility

To be determined

Appearance

Solid powder

Shelf Life

>2 years if stored properly

Storage

Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).

Alternative CAS

122949-49-9 (sodium); 91524-15-1 (free acid)

Biological Target

Irloxacin (Pirfloxacin) is a quinolone antibacterial agent that shows greater activity with an acidic pH and has a good in vitro antimicrobial spectrum against both gram-positive and gram-negative bacteria.

Drug Formulation

To be determined

Elemental Analysis

C, 64.00; H, 4.36; F, 6.33; N, 9.33; O, 15.98

Exact Mass

300.091

HS Tariff Code

2934.99.9001

In Vitro Activity

TBD

In Vivo Activity

Embryotoxicity studies on irloxacin (6-fluorine-7-(pyrrol-1-yl)-1-ethyl-1,4-dihydro-4-oxo-quinolone-3-carboxylic acid, CAS-91524-15-1), a new fluoroquinolone antibacterial agent, were performed in rats and rabbits. Oral administration of irloxacin during the fetal period of organogenesis to pregnant rats and rabbits at dose levels of up to 1000 and 350 mg/kg/d, respectively, elicited no evidence of teratogenicity. During the first days of treatment, transient stasis in body weight increase was observed in rat dams receiving doses of 350 or 1000 mg/kg/d, and reduced food consumption was observed in those receiving 1000 mg/kg/d. Necropsy on day 20 of gestation showed dosage related increase in liver and kidney weights in all rat treated groups. Rabbit dams receiving 350 mg/kg/d showed during the first days of treatment decrease in body weight, and decreased food consumption and faecal output. Also, four females receiving 350 mg/kg/d aborted between days 18 and 20 of gestation. Rat fetuses in the 350 and 1000 mg/kg/d showed decreased body weight, and a decrease in placental weights was observed in the 1000 mg/kg/d group. No retardations or malformations were observed in rat or rabbit fetuses at any tested dose level.
Reference: Arzneimittelforschung. 2003;53(2):121-5. https://pubmed.ncbi.nlm.nih.gov/12642968/

Shipping

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Stock Solution Storage

0-4 °C for short term (days to weeks), or -20 °C for long term (months).